Kaken Pharmaceutical Co Stock Net Income
| KKPCF Stock | USD 26.00 0.00 0.00% |
As of the 10th of February, Kaken Pharmaceutical secures the Mean Deviation of 0.7237, risk adjusted performance of 0.0528, and Standard Deviation of 2.72. Kaken Pharmaceutical Co technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Please verify Kaken Pharmaceutical variance and maximum drawdown to decide if Kaken Pharmaceutical Co is priced some-what accurately, providing market reflects its recent price of 26.0 per share. Given that Kaken Pharmaceutical has variance of 7.41, we recommend you to check Kaken Pharmaceutical's last-minute market performance to make sure the company can sustain itself at a future point.
Kaken Pharmaceutical's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Kaken Pharmaceutical's valuation are provided below:Kaken Pharmaceutical Co does not presently have any fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Kaken |
Kaken Pharmaceutical 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Kaken Pharmaceutical's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Kaken Pharmaceutical.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Kaken Pharmaceutical on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Kaken Pharmaceutical Co or generate 0.0% return on investment in Kaken Pharmaceutical over 90 days. Kaken Pharmaceutical is related to or competes with Luye Pharma, China Shineway, Drägerwerk, and Kossan Rubber. Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japa... More
Kaken Pharmaceutical Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Kaken Pharmaceutical's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Kaken Pharmaceutical Co upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.0209 | |||
| Maximum Drawdown | 26.44 |
Kaken Pharmaceutical Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kaken Pharmaceutical's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Kaken Pharmaceutical's standard deviation. In reality, there are many statistical measures that can use Kaken Pharmaceutical historical prices to predict the future Kaken Pharmaceutical's volatility.| Risk Adjusted Performance | 0.0528 | |||
| Jensen Alpha | 0.104 | |||
| Total Risk Alpha | (0.15) | |||
| Treynor Ratio | 0.3114 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Kaken Pharmaceutical's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Kaken Pharmaceutical February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0528 | |||
| Market Risk Adjusted Performance | 0.3214 | |||
| Mean Deviation | 0.7237 | |||
| Coefficient Of Variation | 1753.96 | |||
| Standard Deviation | 2.72 | |||
| Variance | 7.41 | |||
| Information Ratio | 0.0209 | |||
| Jensen Alpha | 0.104 | |||
| Total Risk Alpha | (0.15) | |||
| Treynor Ratio | 0.3114 | |||
| Maximum Drawdown | 26.44 | |||
| Skewness | 4.71 | |||
| Kurtosis | 36.67 |
Kaken Pharmaceutical Backtested Returns
At this point, Kaken Pharmaceutical is very steady. Kaken Pharmaceutical has Sharpe Ratio of 0.0583, which conveys that the firm had a 0.0583 % return per unit of risk over the last 3 months. We have found sixteen technical indicators for Kaken Pharmaceutical, which you can use to evaluate the volatility of the firm. Please verify Kaken Pharmaceutical's Risk Adjusted Performance of 0.0528, mean deviation of 0.7237, and Standard Deviation of 2.72 to check out if the risk estimate we provide is consistent with the expected return of 0.16%. Kaken Pharmaceutical has a performance score of 4 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 0.47, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Kaken Pharmaceutical's returns are expected to increase less than the market. However, during the bear market, the loss of holding Kaken Pharmaceutical is expected to be smaller as well. Kaken Pharmaceutical right now secures a risk of 2.79%. Please verify Kaken Pharmaceutical Co variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and rate of daily change , to decide if Kaken Pharmaceutical Co will be following its current price movements.
Auto-correlation | -0.08 |
Very weak reverse predictability
Kaken Pharmaceutical Co has very weak reverse predictability. Overlapping area represents the amount of predictability between Kaken Pharmaceutical time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Kaken Pharmaceutical price movement. The serial correlation of -0.08 indicates that barely 8.0% of current Kaken Pharmaceutical price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.08 | |
| Spearman Rank Test | -0.54 | |
| Residual Average | 0.0 | |
| Price Variance | 1.62 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Kaken Pharmaceutical Co reported net income of 9.09 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The net income for all United States stocks is significantly lower than that of the firm.
Kaken Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kaken Pharmaceutical's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Kaken Pharmaceutical could also be used in its relative valuation, which is a method of valuing Kaken Pharmaceutical by comparing valuation metrics of similar companies.Kaken Pharmaceutical is currently under evaluation in net income category among its peers.
Kaken Fundamentals
| Return On Equity | 6.65 | |||
| Return On Asset | 6.36 | |||
| Profit Margin | 12.00 % | |||
| Operating Margin | 22.04 % | |||
| Current Valuation | (68.22 B) | |||
| Shares Outstanding | 37.47 M | |||
| Shares Owned By Insiders | 13.21 % | |||
| Shares Owned By Institutions | 32.63 % | |||
| Price To Earning | 16.87 X | |||
| Price To Book | 0.01 X | |||
| Price To Sales | 0.01 X | |||
| Revenue | 75.78 B | |||
| Gross Profit | 41.58 B | |||
| EBITDA | 19.23 B | |||
| Net Income | 9.09 B | |||
| Cash And Equivalents | 73.7 B | |||
| Total Debt | 3.85 B | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 5.70 X | |||
| Cash Flow From Operations | 13.34 B | |||
| Earnings Per Share | 1.66 X | |||
| Number Of Employees | 1.16 K | |||
| Beta | 0.3 | |||
| Market Capitalization | 980.27 M | |||
| Last Dividend Paid | 1.15 |
About Kaken Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kaken Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kaken Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kaken Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Kaken Pink Sheet
Kaken Pharmaceutical financial ratios help investors to determine whether Kaken Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kaken with respect to the benefits of owning Kaken Pharmaceutical security.